MaxCyte (MXCT) Projected to Post Quarterly Earnings on Wednesday

MaxCyte (NASDAQ:MXCT) is expected to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect MaxCyte to post earnings of ($0.10) per share and revenue of $9.57 million for the quarter. MaxCyte has set its FY 2025 guidance at EPS.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $10.39 million for the quarter, compared to the consensus estimate of $9.05 million. MaxCyte had a negative return on equity of 19.90% and a negative net margin of 110.92%. On average, analysts expect MaxCyte to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Trading Up 2.0%

Shares of NASDAQ:MXCT opened at $2.08 on Tuesday. The stock has a 50 day moving average of $2.20 and a 200 day moving average of $2.88. The company has a market cap of $221.35 million, a PE ratio of -5.20 and a beta of 1.23. MaxCyte has a 12-month low of $1.97 and a 12-month high of $5.20.

Analyst Ratings Changes

A number of equities analysts have weighed in on MXCT shares. Stephens began coverage on shares of MaxCyte in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $6.00 price target for the company. Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Sunday, June 8th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MaxCyte stock. AQR Capital Management LLC grew its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 227.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95,501 shares of the company’s stock after buying an additional 66,323 shares during the period. AQR Capital Management LLC owned 0.09% of MaxCyte worth $261,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.